What could be causing my patient's unexplained weight loss while taking rosuvastatin calcium 20 mg daily, metformin hydrochloride 500 mg (likely twice daily), empagliflozin (Jardiance) 25 mg daily, and sumatriptan succinate 50 mg as needed?

Weight Loss on Current Diabetes Medications: Jardiance is the Primary Culprit

The most likely cause of your patient's weight loss is Jardiance (empagliflozin) 25 mg, which is designed to cause weight loss through increased urinary glucose excretion. This is an expected pharmacologic effect, not a concerning adverse event, unless the weight loss is excessive or accompanied by other symptoms.

Understanding the Weight Effects of Each Medication

Jardiance (Empagliflozin) 25 mg - Primary Driver of Weight Loss

Jardiance causes intentional weight loss of 2-3 kg on average through its mechanism of action as an SGLT2 inhibitor 1, 2. The drug works by blocking glucose reabsorption in the kidneys, leading to urinary glucose excretion of approximately 60-90 grams daily, which translates to 240-360 calories lost per day 3.

• Studies show mean weight loss of 2.37% of baseline body weight with SGLT2 inhibitors 2
• When combined with metformin, weight loss ranges from 2.8-3.8 kg over 24 weeks 4, 5
• At 76 weeks, sustained weight loss of 1.7-2.2 kg persists 6, 7
• This weight loss is considered a therapeutic benefit, particularly for patients with type 2 diabetes and obesity 1, 8

Metformin 500 mg - Modest Weight Loss or Neutral

Metformin contributes to mild weight loss of 2-3% body weight or remains weight-neutral 2, 9, 10. At the 500 mg dose (likely twice daily based on typical prescribing), this effect is minimal:

• The Diabetes Prevention Program showed 2.1 kg weight loss with metformin 850 mg twice daily versus 0.1 kg with placebo 2
• Weight loss is dose-dependent, with doses >1500 mg showing greatest effect 9
• Your patient's 500 mg dose is suboptimal for weight effects 9

Rosuvastatin 20 mg - Weight Neutral

Statins, including rosuvastatin, are weight-neutral medications with no significant impact on body weight 11. This medication can be excluded as a cause.

Sumatriptan 50 mg PRN - Weight Neutral

Sumatriptan for migraine treatment is weight-neutral and used only as needed, making it an unlikely contributor to sustained weight loss.

Clinical Algorithm for Evaluation

Step 1: Quantify the Weight Loss

• If weight loss is <5% of baseline body weight: This is expected and therapeutic with Jardiance
• If weight loss is 5-10% of baseline: Still likely medication-related but warrants monitoring
• If weight loss is >10% or >4 kg/month: Investigate for other causes 8

Step 2: Assess for Concerning Symptoms

Red flags requiring immediate evaluation 3:

• Polyuria with excessive thirst (>normal SGLT2 inhibitor effect)
• Nausea, vomiting, or abdominal pain (possible DKA, though rare with SGLT2 inhibitors in type 2 diabetes)
• Fatigue, weakness, or malaise beyond expected
• Recurrent genital or urinary tract infections
• Signs of volume depletion: orthostatic hypotension, dizziness, decreased skin turgor

Step 3: Laboratory Assessment

Check the following to rule out pathologic causes:

• HbA1c: Assess glycemic control (over-treatment causing excessive glucose loss)
• Basic metabolic panel: Rule out acute kidney injury from volume depletion
• Urinalysis with ketones: Exclude euglycemic DKA (rare but serious SGLT2 inhibitor complication)
• TSH: Rule out hyperthyroidism
• Complete blood count: Assess for metformin-associated vitamin B12 deficiency causing malabsorption 12, 10, 13

Step 4: Review Glycemic Control

• If HbA1c is at or below target (<7% for most patients): Consider reducing Jardiance dose from 25 mg to 10 mg to moderate weight loss 1
• If patient is experiencing hypoglycemia: This combination does not typically cause hypoglycemia unless another secretagogue was recently discontinued 3

Common Pitfalls to Avoid

1. Mistaking therapeutic weight loss for pathology: SGLT2 inhibitors are increasingly used specifically for weight management in diabetes 1, 8. Weight loss of 2-4 kg is expected and beneficial.

2. Overlooking volume depletion: The osmotic diuresis from Jardiance can cause dehydration, especially in older adults 14, 3. Ensure adequate fluid intake.

3. Ignoring vitamin B12 deficiency: Long-term metformin use requires annual B12 monitoring 12, 10, 13. Deficiency can cause anemia, neuropathy, and potentially affect appetite.

4. Missing medication adherence issues: If the patient recently became adherent to previously poorly-taken medications, the weight loss may represent the first time these drugs are working effectively.

Management Recommendations

If weight loss is appropriate and patient is asymptomatic:

• Continue current regimen
• Ensure adequate hydration (8-10 glasses of water daily)
• Monitor weight monthly
• Check vitamin B12 levels if not done in past year 12, 13

If weight loss is excessive or symptomatic:

• Reduce Jardiance from 25 mg to 10 mg daily 1, 15
• Increase metformin dose to 1000 mg twice daily for better glycemic control if needed (this may cause modest additional weight loss but improves diabetes management) 1, 12
• Ensure patient is not restricting calories excessively in combination with medications

If laboratory abnormalities are present:

• Hold Jardiance temporarily if acute kidney injury or volume depletion is present 3
• Supplement vitamin B12 if deficient (1000 mcg daily) 13
• Address any identified pathology

The combination of metformin and Jardiance is guideline-recommended for patients with type 2 diabetes, particularly those with cardiovascular disease or chronic kidney disease 1, 16. The weight loss observed is predominantly a therapeutic effect of Jardiance, which provides cardiovascular and renal protection beyond glycemic control 1, 16.